VISA/VRSA相关耐药进化史及耐药进化代价  

Evolution history and cost of drug resistance related to VISA/VRSA

作　　者：罗云桃 夏启航 王庆忠(综述) 王敬华(审校) LUO Yuntao;XIA Qihang;WANG Qingzhong;WANG Jinghua(Shanghai Center for Clinical Laboratory,Shanghai 200126,China)

机构地区：[1]上海市临床检验中心,上海200126

出　　处：《国际检验医学杂志》2021年第16期2001-2005,共5页International Journal of Laboratory Medicine

基　　金：上海市临床检验中心科研自选课题(2021ZXKT-06)。

摘　　要：金黄色葡萄球菌是最常见的临床病原菌之一,对医疗卫生机构构成重大威胁。1980年以来,万古霉素作为治疗耐甲氧西林金黄色葡萄球菌引起的严重感染的一线药物,成为治疗重症金黄色葡萄球菌感染的有效保障。然而,随着越来越多的万古霉素敏感减弱菌株在全球范围报道,研究人员和医生们开始担心万古霉素中度耐药性金黄色葡萄球菌(VISA)/耐万古霉素金黄色葡萄球菌(VRSA)是否也会暴发。该综述简单回顾了金黄色葡萄球菌耐药性的历史,并归纳了相关VISA/VRSA进化模式和相应的进化改变,提出如何更好地优化临床治疗策略。Staphylococcus aureus is one of the most common clinical pathogens,and it represents a major threat to medical and health institutions.Since 1980,vancomycin has been used as a first-line drug for the treatment of severe infection caused by methicillin resistant Staphylococcus aureus,and it has became the effective therapy against serious Staphylococcus aureus infections.Nevertheless,as growing reports of strains with reduced sensitivity to vancomycin worldwide,researchers and physicians have begun to concern whether vancomycin-intermediate Staphylococcus aureus/vancomycin resistant Staphylococcus aureus(VISA/VRSA)will breakout.In this review,the history of antibiotic resistance of Staphylococcus aureus was briefly reviewed and the evolution mode of VISA/VRSA and the corresponding evolution changes were summarized,and how to optimize the clinical treatment strategy was proposed as well.

关 键 词：金黄色葡萄球菌 万古霉素 万古霉素中度耐药性金黄色葡萄球菌 耐万古霉素金黄色葡萄球菌 

分 类 号：R446.1[医药卫生—诊断学]